Dr Eszter Nagy | Co-Founder, President and CSO
Arsanis Inc | Austria

Dr Eszter Nagy, Co-Founder, President and CSO, Arsanis Inc

Eszter Nagy, MD, PhD, has spent 18 years in biotechnology and has been involved in the discovery and development of numerous biologics for infectious diseases. Her research and development experience includes bacterial pathogenesis, immune response to infections, protein-based vaccines for bacterial pathogens, vaccine adjuvants and anti-infective monoclonal antibodies. Dr. Nagy founded Arsanis in 2010 and built a multi-disciplinary research and pre-clinical team in Vienna that created the current pipeline of the company, including Phase 2 readiness of the leading program ASN100. Prior to Arsanis, Dr. Nagy served in various roles during her 12 years at Intercell AG (now Valneva SE), a biotechnology company focused on the development of prophylactic and therapeutic vaccines against infectious diseases. As Senior Vice President and Global Head of Research for Intercell, she directed research in antigen discovery using genomic, proteomic, and serological methods, pre-clinical development (toxicology and in vitro immune assays), as well as in vivo modeling of a wide range of experimental vaccines and monoclonal antibody therapies targeting bacterial and fungal pathogens. Dr. Nagy co-founded EveliQure Biotechnologies (Vienna) in 2012, and was on the Board of Directors of WittyCell, S.A.S (now part of Abivax, SE), both vaccine development companies. Dr. Nagy is inventor on over 35 published patent families. Prior to joining the biotechnology industry, Dr. Nagy spent 10 years in academic research. She is habil. professor at the University of Vienna, graduate student trainer, and author of over 65 scientific publications. She was Associate Professor at the University Medical School of Pécs and a Visiting Scientist in the Department of Cancer Genetics at the Roswell Park Cancer Institute. Dr. Nagy received her MD and PhD from the University Medical School of Pécs, Hungary, and was a Postdoctoral Fellow at Dartmouth Medical School.


DC Pre-congress WS day April 2 @ 09:00

Incorporating passive immunization with active immunization – The role and use mABs for infectious diseases

Should there really be a distinction between passive and active immunization when responding to diseases and infections therapeutically? Join this workshop to understand how these treatments are increasingly combined and the role of both passive and active immunization in future.

An overview of the scientific rationale & landscape survey of antibodies in preclinical and clinical development for infectious diseases

RSV and bacterial (Sa and Pa) prophylactic monoclonals in development

Current Sa antibodies used effectively for prophylaxis

True Human™ antibody therapy against C. difficile

back to speakers